Ventria provides recombinant proteins derived from the rice plant for medical use
Pixabay / Pexels.com
11 February 2025NewsAmericasLiz Hockley
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
Key ruling in favour of Kansas-based biotech on genetically engineered proteins from China | Court supports ITC position | Small market segments can be substantial enough for domestic industry requirement.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
3 November 2022 Counsel for Ventria sat down with Sarah Speight to explore their landmark win at the International Trade Commission, which led to a US ban for a Chinese company
20 October 2022 Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.
15 September 2022 Kansas-based company wins block on infringing plant-based albumins | Genetically programmed rice expresses human proteins used in immunotherapy drugs, gene therapies and vaccines.